Redeye argues that the lower-than-anticipated sales do not reflect the long-term case of Episurf and that its potential US market entry by H2 this year will be an important milestone for the company. We expect a slower market ramp-up than previously and adjust our estimates, which are now including the Patellofemoral system. Our Fair Value remains intact.